A detailed history of Victory Capital Management Inc transactions in Merus N.V. stock. As of the latest transaction made, Victory Capital Management Inc holds 9,580 shares of MRUS stock, worth $475,742. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,580
Previous 9,780 2.04%
Holding current value
$475,742
Previous $578,000 17.3%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$47.19 - $58.84 $9,438 - $11,768
-200 Reduced 2.04%
9,580 $478,000
Q2 2024

Aug 05, 2024

SELL
$39.81 - $60.2 $110,273 - $166,754
-2,770 Reduced 22.07%
9,780 $578,000
Q1 2024

May 03, 2024

BUY
$28.03 - $51.82 $49,893 - $92,239
1,780 Added 16.53%
12,550 $565,000
Q4 2023

Feb 05, 2024

BUY
$20.06 - $28.66 $216,046 - $308,668
10,770 New
10,770 $296,000
Q4 2022

Feb 09, 2023

SELL
$12.8 - $23.66 $346,496 - $640,476
-27,070 Reduced 39.07%
42,210 $652,000
Q3 2022

Nov 02, 2022

SELL
$18.64 - $28.93 $30,569 - $47,445
-1,640 Reduced 2.31%
69,280 $1.39 Million
Q1 2022

May 04, 2022

BUY
$23.58 - $30.91 $620,154 - $812,933
26,300 Added 58.94%
70,920 $1.88 Million
Q4 2021

Feb 07, 2022

SELL
$20.0 - $32.29 $40,400 - $65,225
-2,020 Reduced 4.33%
44,620 $1.42 Million
Q3 2021

Nov 02, 2021

SELL
$16.48 - $27.23 $7,416 - $12,253
-450 Reduced 0.96%
46,640 $1.03 Million
Q2 2021

Aug 03, 2021

SELL
$20.0 - $25.48 $57,400 - $73,127
-2,870 Reduced 5.74%
47,090 $992,000
Q1 2021

May 04, 2021

BUY
$16.14 - $29.11 $806,354 - $1.45 Million
49,960 New
49,960 $1.04 Million
Q4 2017

Feb 01, 2018

SELL
$14.23 - $21.28 $540,455 - $808,214
-37,980 Closed
0 $0
Q3 2017

Oct 27, 2017

SELL
$13.6 - $19.87 $22,032 - $32,189
-1,620 Reduced 4.09%
37,980 $755,000
Q2 2017

Aug 07, 2017

BUY
N/A
39,600
39,600 $628,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.28B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.